Compare WAL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAL | TGTX |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 8.5B |
| IPO Year | 2005 | 2008 |
| Metric | WAL | TGTX |
|---|---|---|
| Price | $68.46 | $63.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $89.50 | $69.43 |
| AVG Volume (30 Days) | 802.6K | ★ 1.9M |
| Earning Date | 10-19-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | 23.13 | ★ 1746.67 |
| EPS | ★ 6.43 | 0.52 |
| Revenue | ★ $135,800,000.00 | $2,785,000.00 |
| Revenue This Year | $12.69 | $61.95 |
| Revenue Next Year | $4.25 | $35.55 |
| P/E Ratio | ★ $10.83 | $124.71 |
| Revenue Growth | ★ 99.71 | N/A |
| 52 Week Low | $65.82 | $26.76 |
| 52 Week High | $97.23 | $68.03 |
| Indicator | WAL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.96 | 57.99 |
| Support Level | $65.82 | $52.12 |
| Resistance Level | $81.73 | $68.03 |
| Average True Range (ATR) | 2.23 | 3.49 |
| MACD | -0.85 | 0.09 |
| Stochastic Oscillator | 1.05 | 67.11 |
Western Alliance Bancorp provides a full spectrum of customized loan, deposit, and treasury management capabilities, including funds transfer and other digital payment offerings. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.